The FXR/TGR5 dual agonist INT-767 prevents and reverses Western diet-induced NASH and modulates major lipid metabolic pathways in mice

被引：0
|
作者：
Wang, Xiaoxin [1 ]
Libby, Andrew [1 ]
Ranjit, Suman [2 ]
Wang, Dong [1 ]
Luo, Yuhuan [1 ]
Orlicky, David J. [1 ]
McManaman, James [1 ]
Dobrinskikh, Evgenia [1 ]
Gratton, Enrico [2 ]
Young, Mark [3 ]
Adorini, Luciano [3 ]
Levi, Moshe [1 ]
机构：
[1] Univ Colorado, Aurora, CO USA
[2] Univ Calif Irvine, Irvine, CA USA
[3] Intercept Pharmaceut, New York, NY USA
来源：
HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1528
引用
收藏
页码：761A / 762A
页数：2
相关论文
共 27 条
  • [21] INT 767-A NOVEL DUAL FARNESOID-X RECEPTOR (FXR) AND TAKEDA G-PROTEIN-COUPLED RECEPTOR-5 (TGR5) AGONIST ATTENUATES INTESTINAL ISCHEMIA REPERFUSION INJURY
    Canovai, Emilio
    Farre, Ricard
    Accarie, Alison
    De Hertogh, Gert
    Vanuytsel, Tim
    Pirenne, Jacques
    Ceulemans, Laurens J.
    TRANSPLANTATION, 2020, 104 (09) : S167 - S168
  • [22] Coadministration of a GLP-1/Glucagon Receptor Agonist with an FXR Agonist and ACC Inhibitor Reverses Nonalcoholic Steatohepatitis (NASH) in Diet-Induced and Biopsy-Confirmed Mice
    Trevaskis, James L.
    Norlin, Jenny
    Miranda, Diego A.
    Bates, Jamie G.
    Zois, Nora E.
    Veidal, Sanne
    Feigh, Michael
    Latta, Markus
    DIABETES, 2020, 69
  • [23] Dual Farnesoid X Receptor/TGR5 Agonist INT-767 Reduces Liver Injury in the Mdr2-/- (Abcb4-/-) Mouse Cholangiopathy Model by Promoting Biliary HCO3- Output
    Baghdasaryan, Anna
    Claudel, Thierry
    Gumhold, Judith
    Silbert, Dagmar
    Adorini, Luciano
    Roda, Aldo
    Vecchiotti, Stefania
    Gonzalez, Frank J.
    Schoonjans, Kristina
    Strazzabosco, Mario
    Fickert, Peter
    Trauner, Michael
    HEPATOLOGY, 2011, 54 (04) : 1303 - 1312
  • [24] INT-767-A Dual Farnesoid-X Receptor (FXR) and Takeda G Protein-Coupled Receptor-5 (TGR5) Agonist Improves Survival in Rats and Attenuates Intestinal Ischemia Reperfusion Injury
    Canovai, Emilio
    Farre, Ricard
    Accarie, Alison
    Lauriola, Mara
    De Hertogh, Gert
    Vanuytsel, Tim
    Pirenne, Jacques
    Ceulemans, Laurens J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (19)
  • [25] Triple Combination Therapy of GLP-1 Receptor Agonist Semaglutide with an FXR Agonist and AC Inhibitor Reverses Nonalcoholic Steatohepatitis (NASH) in Diet-Induced and Biopsy-Confirmed Mice
    Norlin, Jenny
    Miranda, Diego A.
    Bates, Jamie G.
    Zois, Nora E.
    Veidal, Sanne
    Feigh, Michael
    Trevaskis, James L.
    Latta, Markus
    DIABETES, 2020, 69
  • [26] TRIPLE COMBINATION THERAPY OF GLP-1 RECEPTOR AGONIST SEMAGLUTIDE WITH AN FXR AGONIST AND ACC INHIBITOR REVERSES NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN DIET-INDUCED AND BIOPSY-CONFIRMED MICE.
    Norlin, Jenny Egecioglu
    Lopez, David
    Davidsen, Peter
    Xue, Yaxin
    Campigotto, Federico
    Bates, Jamie
    Zois, Nora Elisabeth
    Veidal, Sanne
    Feigh, Michael
    Latta, Markus
    Trevaskis, James
    HEPATOLOGY, 2020, 72 : 1041 - 1042
  • [27] Saroglitazar, a novel dual PPAR-α/γ agonist, reverses high fat-low protein diet-induced metabolic and cognitive aberrations in C57BL/6J male mice
    Dharavath, Ravinder Naik
    Arora, Shiyana
    Kondepudi, Kanthi Kiran
    Bishnoi, Mahendra
    Chopra, Kanwaljit
    LIFE SCIENCES, 2021, 271
123